NTM Infections Market: Emerging Opportunities đ
Nontuberculous mycobacterial (NTM) infections are an increasing global health challenge, with rising prevalence among older adults and immunocompromised patients. In the U.S., cases surpassed 108,000 in 2023, driving a treatment market worth nearly USD 360 million. ARIKAYCE leads with strong sales, while pipeline therapies like SPR720, MNKD-101, and Epetraborole promise to reshape the landscape. Growing awareness, advanced diagnostics, and innovative therapeutics are fueling significant growth prospects through 2034.
đDiscover detailed insights, key companies, and future forecasts here:
https://www.delveinsight.com/r....eport-store/nontuber
Commentaire
Partagez
